Future development plans include incorporating AI, expanding connectors, and specializing in additional therapeutic areas.

Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.

A Harvard Business School Healthcare Alumni Association Q&A with Paul Ollinger, one of Facebook’s first 250 employees.

Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

The survey shows voters, regardless of party affiliation, still support vaccines and are concerned about the reduction in ...

Shakthi Kumar, EDETEK, Inc.'s Chief Strategy and Business Officer, explores the company's launch of R&D Cloud.

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...

Campaign encourages the use of low-dose aspirin to help reduce the risk of preeclampsia and the complications that come with ...